2026 Commercial Insurance Innovative Drug List
Published Nov 14, 2026 alongside the 2026 NRDL (28 total drugs in the full 2026 PDF vs 19 in 2025). This page highlights verified launch-sample additions, indication expansions, and 2025 exits/graduations into basic NRDL.
Policy scope note: Inclusion in the NHSA Commercial Health Insurance Innovative Drug List indicates national catalog listing for commercial insurer reference (basic medical insurance funds do not reimburse these drugs). Actual patient reimbursement depends on the specific commercial health insurance policy contract.
2026 Commercial List — Verified Sample Additions & Expansions (4)
Effective Jan 1, 2027| No. & Brand | Generic Name | MAH & Authorized Entity | Listed Indication Scope | Agreement & Status | Source |
|---|---|---|---|---|---|
#13 源瑞达 Indication Expanded | Inaticabtagene autoleucel 纳基奥仑赛注射液 | Juventas Cell Therapy Ltd. Authorized: 合源生物科技股份有限公司 | Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy. Show Chinese catalog text本品适用于成人复发或难治性B细胞急性淋巴细胞白血病。本品适用于经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤,包括:弥漫大B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的大B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤。 | Jan 1, 2026 – Dec 31, 2027 Announced · Effective Jan 1, 2027 | NHSA · PDF p.3 Verified 2026-11-20 |
#24 Wainua / 万诺维 Newly Added 2026 | Eplontersen sodium 依普隆特生钠注射液 | AstraZeneca AB Authorized: 阿斯利康(无锡)贸易有限公司 | Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN). Show Chinese catalog text本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。 | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-20 |
#25 Qalsody / 凯盛迪 Newly Added 2026 | Tofersen 托夫生注射液 | Biogen MA Inc. Authorized: 渤健生物科技(上海)有限公司 | Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene. Show Chinese catalog text本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。 | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.4 Verified 2026-11-20 |
#28 Pluvicto / 派威妥 Newly Added 2026 | Lutetium (177Lu) vipivotide tetraxetan 镥[177Lu]特昔维匹肽注射液 | Novartis Pharma Schweiz AG Authorized: 诺华医药科技(浙江)有限公司 | Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy. Show Chinese catalog text本品适用于以下成人患者:1.既往接受雄激素受体通路抑制剂(ARPI)后疾病进展且适合延迟化疗的前列腺特异性膜抗原(PSMA)阳性转移性去势抵抗性前列腺癌(mCRPC);2.既往接受雄激素受体通路抑制和紫杉类化疗后疾病进展的PSMA阳性mCRPC。 | Jan 1, 2027 – Dec 31, 2028 Announced · Effective Jan 1, 2027 | NHSA · PDF p.5 Verified 2026-11-20 |
2025 Commercial List Entries Not Carried Into 2026 (3)
Verified by diffing the official 2025 Commercial List PDF (19 drugs) against the 2026 Commercial List PDF (28 drugs). Two therapies graduated directly into the 2026 basic NRDL.
| 2025 No. & Brand | Generic Name | 2026 Outcome | MAH | 2025 Source |
|---|---|---|---|---|
2025 #2 海普益 | Sapropterin dihydrochloride 盐酸沙丙蝶呤片 | Graduated to 2026 Basic NRDL (#42) Reimbursed under basic medical insurance effective Jan 1, 2027. | Shandong New Time Pharmaceutical Co., Ltd. | NHSA · PDF p.2 |
2025 #12 Carteyva / 倍诺达 | Relmacabtagene autoleucel 瑞基奥仑赛注射液 | Graduated to 2026 Basic NRDL (#297) Reimbursed under basic medical insurance effective Jan 1, 2027. | JW Therapeutics (Shanghai) Co., Ltd. | NHSA · PDF p.4 |
2025 #16 Tazverik / 达唯珂 | Tazemetostat hydrobromide 氢溴酸他泽司他片 | Omitted from 2026 Commercial List Not listed in 2026 Commercial List or 2026 NRDL. | Epizyme, Inc. | NHSA · PDF p.4 |